Tiziana Life Sciences Ltd
NASDAQ:TLSA · NASDAQ Global Market
+$0.03 today
Vol 0.29M · Avg 0.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-35444.2%
avg -3421.2%
ROIC
-4189.8%
avg -571.1%
ROA
-160.3%
avg -170.4%
Analysis
ROA is currently the strongest return metric at -160.3% versus its period average of -170.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ivor R. Elrifi | Chief Executive Officer & Executive Director | $131,000.00 | — | — | — | — |
Gabriele Marco Antonio Cerrone | Founder & Executive Chairman | — | — | 54 | $0.00 | <0.01% |
William Edward Tente | Chief Regulatory Officer | — | — | 68 | — | — |
Keeren Shah | Chief Operating Officer & Chief Financial Officer | — | — | 50 | $0.00 | <0.01% |
Napoleone Ferrara | Member of Scientific Advisory Board | — | — | 69 | — | — |
Richard K. Kim | Chief Medical Officer | — | — | 55 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$509.75M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$264.46M
MacroGenics, Inc.
NASDAQ:MGNX
$260.93M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$214.13M
Coya Therapeutics, Inc.
NASDAQ:COYA
$89.04M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$71.21M
eXoZymes, Inc.
NASDAQ:EXOZ
$62.62M
OKYO Pharma Limited
NASDAQ:OKYO
$60.62M
Estrella Immunopharma, Inc.
ESLA
$43.68M
Anebulo Pharmaceuticals, Inc.
ANEB
$15.92M
Who manages TLSA?
Tiziana Life Sciences Ltd (TLSA) lists 6 active executives. The top listed executive is Gabriele Marco Antonio Cerrone, Founder & Executive Chairman.
Are TLSA insiders buying or selling?
Recent insider activity shows net buying of $16,650.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.